Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

NCT07126158 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07126158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07126158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
April 10, 2026
Completion date
April 30, 2030
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the pancreas, pancreas cancer, pancreatic adenocarcinoma, pancreatic cancer